Ontology highlight
ABSTRACT:
SUBMITTER: Furmick JK
PROVIDER: S-EPMC3479356 | biostudies-literature | 2012 Sep
REPOSITORIES: biostudies-literature
Furmick Julie K JK Kaneko Ichiro I Walsh Angela N AN Yang Joanna J Bhogal Jaskaran S JS Gray Geoffrey M GM Baso Juan C JC Browder Drew O DO Prentice Jessica L S JL Montano Luis A LA Huynh Chanh C CC Marcus Lisa M LM Tsosie Dorian G DG Kwon Jungeun S JS Quezada Alexis A Reyes Nicole M NM Lemming Brittney B Saini Puneet P van der Vaart Arjan A Groy Thomas L TL Marshall Pamela A PA Jurutka Peter W PW Wagner Carl E CE
ChemMedChem 20120901 9
The synthesis of halogenated analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (1), known commonly as bexarotene, and their evaluation for retinoid X receptor (RXR)-specific agonist performance is described. Compound 1 is FDA approved to treat cutaneous T-cell lymphoma (CTCL); however, bexarotene treatment can induce hypothyroidism and elevated triglyceride levels, presumably by disrupting RXR heterodimer pathways for other nuclear receptors. The novel h ...[more]